Your session is about to expire
← Back to Search
Chemotherapy for Head and Neck Cancer (APA Trial)
APA Trial Summary
This trial is testing the efficacy and toxicity of two different chemotherapy treatments for head and neck squamous cell carcinoma (HNSCC), with the addition of a third arm testing a novel treatment approach for a subgroup with a very favorable prognosis.
APA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAPA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 & 3 trial • 191 Patients • NCT01881230APA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT
- Group 2: Arm 2: nab-Paclitaxel (A) + CRT
- Group 3: Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What ailments are most commonly treated with nab-Paclitaxel?
"Nab-Paclitaxel is a popular treatment for metastatic neoplasms and various other ailments such as thymoma, acquired immunodeficiency syndrome, and advanced bladder cancer."
Is recruitment still on-going for this experiment?
"No longer accepting participants, this trial was first posted in April 2016 and last updated on June 2nd 2022. For other clinical trials for oral squamous cell carcinoma there are currently 3008 studies recruiting patients, while 1477 medical centres accept enrollees for nab-Paclitaxel research."
What is the sample size for this clinical research?
"At this time, no more candidates are being sought for the clinical trial. Initially posted on April 13th 2016 and last updated June 2nd 2022, it has since been concluded. If you're still in search of a study to participate in, 3008 studies with oral squamous cell carcinoma and 1477 trials involving nab-paclitaxel are recruiting right now."
Has nab-Paclitaxel been granted authorization by the Food and Drug Administration?
"Nab-Paclitaxel received a safety rating of 2 on our scale, in light of the fact it is only at Phase 2 and there has yet to be any evidence indicating its efficacy."
Share this study with friends
Copy Link
Messenger